USANA Health Sciences, Inc. (NYSE:USNA) Director John Turman Fleming Sells 500 Shares

USANA Health Sciences, Inc. (NYSE:USNA) Director John Turman Fleming sold 500 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $33.30, for a total value of $16,650.00. Following the completion of the sale, the director now owns 4,026 shares of the company’s stock, valued at approximately $134,065.80. This represents a 11.05 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

USANA Health Sciences Price Performance

Shares of USANA Health Sciences stock opened at $30.38 on Friday. The business has a 50-day moving average of $32.79 and a 200-day moving average of $36.05. The company has a market capitalization of $579.12 million, a PE ratio of 10.74, a P/E/G ratio of 0.93 and a beta of 0.98. USANA Health Sciences, Inc. has a 1-year low of $27.71 and a 1-year high of $50.32.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.15. The business had revenue of $213.61 million during the quarter, compared to the consensus estimate of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. On average, equities analysts expect that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On USANA Health Sciences

A number of hedge funds have recently bought and sold shares of USNA. R Squared Ltd acquired a new position in USANA Health Sciences in the fourth quarter worth about $28,000. Safe Harbor Fiduciary LLC bought a new position in USANA Health Sciences in the third quarter worth about $30,000. KBC Group NV lifted its holdings in USANA Health Sciences by 96.6% in the third quarter. KBC Group NV now owns 1,056 shares of the company’s stock worth $40,000 after acquiring an additional 519 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in USANA Health Sciences in the fourth quarter worth about $83,000. Finally, Quantbot Technologies LP bought a new position in USANA Health Sciences in the fourth quarter worth about $132,000. 54.25% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. DA Davidson lowered their price target on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating for the company in a report on Thursday, February 27th. StockNews.com downgraded USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th. Finally, Sidoti downgraded USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.